Bibliographic Details
| Title: |
Stability Indicating Assay Method for the Quantitative Determination of Olaparib in Bulk and Pharmaceutical Dosage Form. |
| Authors: |
CHAUDHARY, Antima1, TONK, Rajiv1, DAGUR, Pankaj2, DEY, Suddhasattya3, GHOSH, Manik2 manik@bitmesra.ac.in |
| Source: |
Turkish Journal of Pharmaceutical Sciences. Oct2022, Vol. 19 Issue 5, p488-497. 10p. |
| Subject Terms: |
*DOSAGE forms of drugs, *OLAPARIB, *HYDROCHLOROTHIAZIDE, *POLY(ADP-ribose) polymerase, *AMMONIUM acetate, *LIQUID chromatography |
| Abstract: |
Objectives: Olaparib is an orally active poly (ADP-ribose) PARP (polymerases) inhibitor known to destroy cancer cells with BRCA1 or BRCA2 deficiency. An authentic, fast, distinct, and reliable reverse phase-high performance liquid chromatography (RP-HPLC) method was developed and promptly validated in tablet formulations for olaparib estimation. Materials and Methods: The proposed method focuses on the separation of olaparib in reverse phase mode using a Waters symmetry C18 (150 x 4.6 mm, 5 µm) analytical column with a flow rate of 1.0 mL/min and the injection volume was kept at 20 µL. The optimized mobile phase consists of ammonium acetate buffer (pH adjusted to 3.5 by glacial acetic acid): methanol in the ratio of 50:50 v/v. Results: The eluents were measured at 254 nm and the retention time for the drug encircled was about 4.32 min. The stress degradation studies of olaparib were conducted under acidic, alkaline, oxidative, photolytic and thermal conditions to demonstrate the stability of the drug. The regression value of 0.998 showed that the developed method was linear over the range of 80 µg/mL to 120 µg/mL. The developed RP-HPLC method is accurate and precise. The method was statistically validated as per International Conference on Harmonization guidelines. Conclusion: The proposed method is suitable and can be applied for the quantitative estimation of olaparib without any interference of the excipients used in the drug formulations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Turkish Journal of Pharmaceutical Sciences is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
